The power and the promise of cell reprogramming: Personalized autologous body organ and cell transplantation

dc.contributor.authorÁlvarez Palomo, Ana Belén
dc.contributor.authorLucas, Michaela
dc.contributor.authorDilley, Rodney J.
dc.contributor.authorMcLenachan, Samuel
dc.contributor.authorChen, Fred K.
dc.contributor.authorRequena Osete, Jordi
dc.contributor.authorFarrera Sal, Martí
dc.contributor.authorLucas, Andrew
dc.contributor.authorÁlvarez, Iñaki
dc.contributor.authorJaraquemada, Dolores
dc.contributor.authorEdel, Michael John
dc.date.accessioned2017-12-13T18:02:05Z
dc.date.available2017-12-13T18:02:05Z
dc.date.issued2014-04-04
dc.date.updated2017-12-13T18:02:06Z
dc.description.abstractReprogramming somatic cells to induced pluripotent stem cells (iPSCs) or direct reprogramming to desired cell types are powerful and new in vitro methods for the study of human disease, cell replacement therapy, and drug development. Both methods to reprogram cells are unconstrained by the ethical and social questions raised by embryonic stem cells. iPSC technology promises to enable personalized autologous cell therapy and has the potential to revolutionize cell replacement therapy and regenerative medicine. Potential applications of iPSC technology are rapidly increasing in ambition from discrete cell replacement applications to the iPSC assisted bioengineering of body organs for personalized autologous body organ transplant. Recent work has demonstrated that the generation of organs from iPSCs is a future possibility. The development of embryonic-like organ structures bioengineered from iPSCs has been achieved, such as an early brain structure (cerebral organoids), bone, optic vesicle-like structures (eye), cardiac muscle tissue (heart), primitive pancreas islet cells, a tooth-like structure (teeth), and functional liver buds (liver). Thus, iPSC technology offers, in the future, the powerful and unique possibility to make body organs for transplantation removing the need for organ donation and immune suppressing drugs. Whilst it is clear that iPSCs are rapidly becoming the lead cell type for research into cell replacement therapy and body organ transplantation strategies in humans, it is not known whether (1) such transplants will stimulate host immune responses; and (2) whether this technology will be capable of the bioengineering of a complete and fully functional human organ. This review will not focus on reprogramming to iPSCs, of which a plethora of reviews can be found, but instead focus on the latest developments in direct reprogramming of cells, the bioengineering of body organs from iPSCs, and an analysis of the immune response induced by iPSC-derived cells and tissues.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec661432
dc.identifier.issn2077-0383
dc.identifier.pmid26237380
dc.identifier.urihttps://hdl.handle.net/2445/118715
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm3020373
dc.relation.ispartofJournal of Clinical Medicine, 2014, vol. 3, num. 2, p. 373-387
dc.relation.urihttps://doi.org/10.3390/jcm3020373
dc.rightscc-by (c) Álvarez Palomo, Ana Belén et al., 2014
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Biomedicina)
dc.subject.classificationBioenginyeria
dc.subject.classificationTrasplantament d'òrgans
dc.subject.classificationTeràpia cel·lular
dc.subject.otherBioengineering
dc.subject.otherTransplantation of organs
dc.subject.otherCellular therapy
dc.titleThe power and the promise of cell reprogramming: Personalized autologous body organ and cell transplantation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
661432.pdf
Mida:
241.33 KB
Format:
Adobe Portable Document Format